Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:collaboration
gptkb:Therakos,_Inc. 2017 2018 2019 2020 2021 2022 2023 partnership investment merger buyout equity stake joint venture co-marketing consolidation strategic alliance purchase licensing agreement spin-off asset purchase divestiture merger of equals reverse merger stock purchase strategic investment takeover co-development co-distribution co-investment co-licensing co-promotion joint acquisition |
| gptkbp:CEO |
gptkb:Mark_Trudeau
2015 President_of_Mallinckrodt_Pharmaceuticals |
| gptkbp:employees |
approximately 3,000
|
| gptkbp:focusArea |
rare diseases
autoimmune diseases central nervous system disorders pain management |
| gptkbp:founded |
1867
|
| gptkbp:headquarters |
gptkb:United_States
gptkb:St._Louis,_Missouri |
| https://www.w3.org/2000/01/rdf-schema#label |
Mallinckrodt, Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
$1.1 billion (2021)
|
| gptkbp:parentCompany |
gptkb:Mallinckrodt_plc
|
| gptkbp:products |
specialty pharmaceuticals
|
| gptkbp:revenue |
$2.5 billion (2020)
|
| gptkbp:stockSymbol |
MNK
|
| gptkbp:subsidiary |
gptkb:Mallinckrodt_Pharmaceuticals
|
| gptkbp:tradedOn |
gptkb:New_York_Stock_Exchange
|
| gptkbp:website |
www.mallinckrodt.com
|